Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166359 | 0.79 | TDP1 (0.32) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL4202200 | 0.79 | PTGS1 (0.31) | — | |
| Ethylene Glycol SCHEMBL1230351 | 0.76 | — | — | |
| Ethylene Glycol SCHEMBL725031 | 0.76 | — | — | |
| Ethylene Glycol SCHEMBL707152 | 0.76 | — | — | |
| SCHEMBL23244687 | 0.75 | LMNA (0.37) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL2317312 | 0.75 | LMNA (0.37) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL553468 | 0.70 | LMNA (0.37) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL553467 | 0.70 | LMNA (0.37) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL10814793 | 0.70 | TDP1 (0.32) | TDP1LMNAALOX15BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN THERAPEUTICS, INC. | 2011-02-10 | — | — | US | claimed |
| EP-2117513-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | Carbylan Biosurgery, Inc. (US) | 2009-11-18 | — | — | EP | claimed |
| WO-2008098019-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN BIOSURGERY, INC. (US) | 2008-08-14 | — | — | WO | claimed |
| US-9980977-B2 | Modified hyaluronic acid polymer compositions and related methods | CARBYLAN THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170224708-A1 | MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS | CARBYLAN BIOSURGERY, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9446136-B2 | Modified hyaluronic acid polymer compositions and related methods | CARBYLAN THERAPEUTICS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2016144169-A1 | TRIFUNCTIONAL COATING | DSM IP ASSETS B.V. (NL) | 2016-09-15 | — | — | WO | disclosed |
| US-20160193342-A1 | Modified Hyaluronic Acid Polymer Compositions and Related Methods | CARBYLAN BIOSURGERY, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20150352142-A1 | STABILIZED COMPOSITIONS COMPRISING HYALURONIC ACID | CARBYLAN THERAPEUTICS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9192678-B2 | Modified hyaluronic acid polymer compositions and related methods | CARBYLAN THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2943531-A1 | STABILIZED COMPOSITIONS COMPRISING HYALURONIC ACID | Carbylan Therapeutics, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20090117078-A1 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090105193-A1 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090017091-A1 | STERILE HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS | CARBYLAN THERAPEUTICS, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2009005790-A2 | STERILE THIOL-DERIVATIZED HYALURONIC ACID POLYMER COMPOSITIONS AND USES THEREOF | CARBYLAN BIOSURGERY, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008098019-A2 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | CARBYLAN BIOSURGERY, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1539799-A4 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | UNIV UTAH RES FOUND (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20050176620-A1 | crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound. | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-08-11 | — | — | US | disclosed |
| EP-1539799-A2 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | The University of Utah Research Foundation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004037164-A2 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017091-A1 | STERILE HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS | CD44, ACR, HIRA | TDP1 2961/4885LMNA 3863/4885ALOX15 595/4885 |
| US-20090117078-A1 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | APEX1, GPX4, LIG4 | TDP1 656/4885LMNA 2843/4885ALOX15 95/4885 |
| US-20150352142-A1 | STABILIZED COMPOSITIONS COMPRISING HYALURONIC ACID | CD44, SERPINA6, MUC1 | TDP1 3311/4885LMNA 1210/4885ALOX15 271/4885 |
| US-20160193342-A1 | Modified Hyaluronic Acid Polymer Compositions and Related Methods | CD44, HPSE, HPGDS | TDP1 3865/4885LMNA 1055/4885ALOX15 94/4885 |
| US-20090105193-A1 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | APEX1, GPX4, MGMT | TDP1 732/4885LMNA 2686/4885ALOX15 122/4885 |
| US-20050176620-A1 | crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound. | TXN2, APEX1, MGMT | TDP1 492/4885LMNA 2276/4885ALOX15 676/4885 |
| US-20170224708-A1 | MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS | CD44, HPSE, HPGDS | TDP1 3865/4885LMNA 1055/4885ALOX15 94/4885 |
| US-20110033540-A1 | POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS | BMP2, BMP6, BMP4 | TDP1 2061/4885LMNA 1101/4885ALOX15 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.